Company / Operating Margin
Seres Therapeutics, Inc. Operating Margin History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-44.5%
FY2023
5-year range
-354.8% / -44.5%
FY2019-FY2023
Trend
+83.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin has fluctuated over the past 8 years, ranging from -426.5% in FY2018 to -44.5% in FY2023.
Based on SEC 10-K filings.
-44.5% in FY2023 with a 5-year CAGR of +382.0%.
Improved from -208.3% to -44.5% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- +310.3pp
- 5-Year Change
- +382.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, operating margin increased 83.2% year-over-year.
- Lowest operating margin in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2023 | -44.5% | +83.2% |
| FY2022 | -265.3% | -27.4% |
| FY2021 | -208.3% | +41.3% |
| FY2020 | -354.8% | -24.6% |
| FY2019 | -284.7% | +33.2% |
| FY2018 | -426.5% | -69.2% |
| FY2017 | -252.0% | -263.7% |
| FY2016 | -69.3% | - |
| FY2015 | - | - |
As of FY2023 · SEC Form 10-K · Last checked Jun 24, 2026